RNAiドラッグデリバリーの世界市場

RNAiドラッグデリバリーの世界市場は2030年までに33億米ドルに達する

2024年に11億米ドルと推定されるRNAiドラッグデリバリーの世界市場は、2024年から2030年にかけてCAGR 19.8%で成長し、2030年には33億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるナノ粒子ドラッグデリバリー技術は、CAGR 22.3%を記録し、分析期間終了までに16億米ドルに達すると予測されます。肺ドラッグデリバリー技術分野の成長率は、分析期間中CAGR17.0%と推定されます。

米国市場は3億220万米ドルと推定、中国はCAGR26.3％で成長予測

米国のRNAiドラッグデリバリー市場は、2024年に3億220万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億5,560万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは26.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.4%と18.0%と予測されています。欧州では、ドイツがCAGR約15.8%で成長すると予測されています。

世界の「RNAiドラッグデリバリー」市場- 主要動向と促進要因のまとめ

現代の治療においてRNAiデリバリーメカニズムが重要な理由とは？

RNA干渉（RNAi）は遺伝子サイレンシングに革命をもたらし、病気を引き起こす遺伝子を比類のない精度で阻害する強力なツールを提供しました。しかし、RNAi療法をベンチからベッドサイドに移行させるための核心は、効果的なデリバリー・システムにあります。ネイキッドsiRNAは血流中では本質的に不安定であり、ヌクレアーゼによって急速に分解されやすく、腎濾過によってクリアランスされやすいです。さらに、siRNAはマイナスに帯電しており、親水性であるため、細胞膜を通過する上で大きな障害となります。この課題により、siRNAを保護するだけでなく、組織特異性、オフターゲット効果の最小化、効率的な細胞内取り込みを保証するデリバリー・プラットフォームの設計に関する熱心な研究が推進されています。脂質ナノ粒子（LNPs）、ポリマーベースのキャリア、そしてGalNAc-siRNAのようなコンジュゲーション戦略は、この進化における重要な手法です。LNPは肝臓へのターゲティングに優れており、高分子キャリアは汎用性と構造可変性を提供します。さらに、細胞外小胞やアプタマーベースのキャリアは、生物学的な着想を得た、免疫原性の低い代替物として出現しつつあります。最適化されたデリバリー・システムがなければ、RNAiの治療可能性はほとんど未開拓のままであり、それゆえデリバリー・サイエンスはRNAiベースの医薬品開発において不可欠な柱となっています。

脂質ナノ粒子とポリマーの革新は、RNAiドラッグデリバリーの展望を再構築しているか？

脂質ベースのナノ粒子の改良は、RNAi医薬品の臨床的成功を可能にする上で中心的な役割を担ってきました。特に、遺伝性トランスサイレチンを介するアミロイドーシスを治療するためにLNPを使用する、FDA認可の最初のsiRNA治療薬であるパティシランの承認がそうです。このナノ粒子はsiRNAをカプセル化し、酵素分解から保護し、標的細胞内ではエンドソームからの脱出を促進します。主な技術革新は、生体適合性と生体内分布を改善し、投与回数を減らすことを可能にするために、イオン化可能な脂質を強化することでした。これと並行して、ポリエチレンイミン（PEI）、ポリ乳酸-グリコール酸（PLGA）、デンドリマーなどのポリマーベースのシステムが、RNAiの輸送に適合するように改良されてきました。これらは、適切に改良された場合、放出が制御され、全身毒性が軽減されるという利点があります。さらに、pH応答性ポリマーや、特定の細胞内環境に遭遇した時にsiRNAを放出する刺激感受性キャリアーも改良されています。脂質とポリマーの両成分を組み合わせたハイブリッドシステムの開発は、両者の長所を活かすことを目的としています。また、呼吸器疾患や消化器疾患に対して、局所的で非侵襲的なデリバリーを可能にする、粘膜や鼻腔内デリバリーシステムをターゲットとした調査も行われています。全体として、LNPとポリマーにおける技術革新は、幅広い適応症にわたってRNAi治療薬の治療指標を拡大する上で中心的な役割を担っています。

特定の臓器や疾患をターゲットにすることで、RNAiデリバリーの可能性を最大限に引き出すことができるのか？

RNAiベースの治療法の成功は、その臓器や細胞タイプ特異性によって左右されるようになってきています。肝臓は、その柵状内皮とナノ粒子集積に対する自然な親和性により、今日でもRNAi薬剤の主要な標的であり続けています。肝細胞のアシアロ糖タンパク質受容体（ASGPR）経路を利用するGalNAcコンジュゲーション技術は、siRNAの皮下送達を簡素化し、慢性肝疾患に対する簡便な標的治療を可能にしました。肝への応用にとどまらず、研究者たちは脳、肺、目といった到達しにくい組織へのデリバリーを積極的に模索しています。血液脳関門（BBB）の浸透は依然として大きなハードルであるが、リガンドを標的としたナノ粒子、マイクロバブルを用いた集束超音波、エクソソームをベースとしたキャリアが前臨床モデルで有望視されています。肺疾患では、エアロゾル化RNAi製剤が勢いを増しており、非侵襲的で部位特異的な投与が可能です。同様に、眼への投与では、持続的かつ局所的な遺伝子サイレンシングを可能にする生分解性インプラントやハイドロゲルシステムが役立っています。がんは依然として魅力的ではあるが、複雑なターゲットです。腫瘍微小環境の不均一性と免疫障壁のために、部位特異的な蓄積、トリガー放出、最小限の免疫原性が可能なスマート・デリバリー・システムの設計が必要とされています。疾患特異的な生理機能に合わせて送達システムを調整することは、肝疾患以外にもRNAiの臨床的可能性を最大限に引き出すために不可欠です。

RNAi市場の急拡大は需要シフトと技術的ブレークスルーによるものか？

世界のRNAiドラッグデリバリー市場の成長は、技術の進歩、エンドユーズパターンの進化、消費者の需要の変化に関連するいくつかの要因によって牽引されています。主要な促進要因は、慢性疾患や遺伝性疾患の急激な増加であり、RNAiが得意とする精密治療に対する緊急のニーズが生まれています。バイオファーマ大手や新興企業による研究開発投資の増加は、臨床パイプラインを加速させており、いくつかのRNAi治療薬はすでに後期臨床試験を終えています。さらに、ハイスループット・スクリーニングとバイオインフォマティクス・ツールの進歩により、新規RNAi標的の迅速な同定が可能になり、開発期間が短縮されています。エンドユーザー側では、ヘルスケア業界の個別化医療へのシフトが、カスタマイズ可能なRNAi治療への需要を押し上げています。さらに、皮下や経鼻といった低侵襲の投与経路が好まれるようになり、送達システムの技術革新が加速しています。また、初期のRNAi医薬品の商業的成功は投資家の信頼を高め、RNAiに特化したバイオテクノロジー企業への資金提供の増加を引き起こしています。規制当局も、希少疾患をターゲットとするRNAi医薬品の早期承認や希少疾病指定を行うなど、より寛容になってきています。さらに、特に北米と欧州では、有利な償還の枠組みが患者のアクセスを拡大しています。研究および診断におけるRNAiの採用の増加は市場をさらに後押しし、現代の医薬品イノベーションにおいて最もダイナミックなセグメントのひとつとなっています。

セグメント

技術（ナノ粒子ドラッグデリバリー、肺ドラッグデリバリー、核酸ドラッグデリバリー、アプタマー・ドラッグデリバリー）、用途（感染症、心臓病、腫瘍、神経、眼科、泌尿器、代謝疾患、その他の用途）

調査対象企業の例（全39件）

• Alnylam Pharmaceuticals
• Aro Biotherapeutics
• Arrowhead Pharmaceuticals
• AstraZeneca
• BioNTech SE
• Dicerna Pharmaceuticals（acquired by Novo Nordisk）
• DTx Pharma（acquired by Novartis）
• GlaxoSmithKline（GSK）
• Ionis Pharmaceuticals
• Moderna, Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Roche Holding AG
• Sanofi
• Sarepta Therapeutics
• Silence Therapeutics
• Sirnaomics
• Switch Therapeutics

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global RNAi Drug Delivery Market to Reach US$3.3 Billion by 2030

The global market for RNAi Drug Delivery estimated at US$1.1 Billion in the year 2024, is expected to reach US$3.3 Billion by 2030, growing at a CAGR of 19.8% over the analysis period 2024-2030. Nanoparticle Drug Delivery Technology, one of the segments analyzed in the report, is expected to record a 22.3% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Pulmonary Drug Delivery Technology segment is estimated at 17.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$302.2 Million While China is Forecast to Grow at 26.3% CAGR

The RNAi Drug Delivery market in the U.S. is estimated at US$302.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$755.6 Million by the year 2030 trailing a CAGR of 26.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.4% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.8% CAGR.

Global "RNAi Drug Delivery" Market - Key Trends & Drivers Summarized

What Makes RNAi Delivery Mechanisms So Crucial in Modern Therapeutics?

RNA interference (RNAi) has revolutionized gene silencing, offering a powerful tool to inhibit disease-causing genes with unmatched precision. However, the crux of translating RNAi therapies from bench to bedside lies in effective delivery systems. Naked siRNA is inherently unstable in the bloodstream, prone to rapid degradation by nucleases and clearance via renal filtration. Additionally, siRNAs are negatively charged and hydrophilic, posing a major hurdle to crossing cellular membranes. This challenge has propelled intense research into designing delivery platforms that not only protect siRNA but also ensure tissue specificity, minimal off-target effects, and efficient cellular uptake. Lipid nanoparticles (LNPs), polymer-based carriers, and conjugation strategies like GalNAc-siRNA represent key modalities in this evolution. Each platform comes with distinct advantages-LNPs are excellent for liver targeting, while polymeric carriers offer versatility and structural tunability. Moreover, extracellular vesicles and aptamer-based carriers are emerging as bio-inspired, less immunogenic alternatives. Without optimized delivery systems, the therapeutic potential of RNAi remains largely untapped, hence making delivery science an indispensable pillar in RNAi-based drug development.

Are Innovations in Lipid Nanoparticles & Polymers Reshaping the RNAi Drug Delivery Landscape?

The refinement of lipid-based nanoparticles has taken center stage in enabling clinical success of RNAi drugs, most notably with the approval of patisiran, the first FDA-sanctioned siRNA therapeutic, which uses LNPs to treat hereditary transthyretin-mediated amyloidosis. These nanoparticles encapsulate siRNA, shielding it from enzymatic degradation and facilitating endosomal escape once inside the target cell. Key innovations have involved enhancing ionizable lipids to improve biocompatibility and biodistribution, allowing for reduced dosing frequencies. Parallel to this, polymer-based systems such as polyethyleneimine (PEI), poly(lactic-co-glycolic acid) (PLGA), and dendrimers have been adapted to suit RNAi transport. These offer the advantage of controlled release and reduced systemic toxicity when modified appropriately. Further enhancements include pH-responsive polymers and stimuli-sensitive carriers that release siRNA upon encountering specific intracellular environments. The development of hybrid systems combining both lipid and polymeric components aims to leverage the best features of both. Research is also targeting mucosal and intranasal delivery systems, allowing localized, non-invasive delivery for respiratory or gastrointestinal diseases. Overall, technological innovation in LNPs and polymers is central to expanding the therapeutic index of RNAi therapeutics across a wide range of indications.

Can Targeting Specific Organs and Diseases Unlock the Full Potential of RNAi Delivery?

The success of RNAi-based therapies is increasingly dictated by their capacity for organ and cell-type specificity. The liver, owing to its fenestrated endothelium and natural affinity for nanoparticle accumulation, remains the primary target for RNAi drugs today. GalNAc conjugation technology, which exploits the asialoglycoprotein receptor (ASGPR) pathway in hepatocytes, has simplified subcutaneous delivery of siRNA, enabling convenient and targeted therapy for chronic liver diseases. Beyond hepatic applications, researchers are actively exploring delivery to hard-to-reach tissues such as the brain, lungs, and eyes. Blood-brain barrier (BBB) penetration remains a significant hurdle; however, ligand-targeted nanoparticles, focused ultrasound with microbubbles, and exosome-based carriers are showing promise in preclinical models. In pulmonary conditions, aerosolized RNAi formulations are gaining momentum, offering non-invasive and site-specific administration. Similarly, ocular delivery is benefiting from biodegradable implants and hydrogel systems that allow for sustained, localized gene silencing. Cancer remains a compelling but complex target-tumor microenvironment heterogeneity and immune barriers have necessitated the design of smart delivery systems capable of site-specific accumulation, triggered release, and minimal immunogenicity. Tailoring delivery systems for disease-specific physiology is critical to unlocking RNAi’s full clinical potential beyond hepatic disorders.

Is the Rapid Expansion of the RNAi Market Fuelled by Demand Shifts and Tech Breakthroughs?

The growth in the global RNAi drug delivery market is driven by several factors related to technological advancements, evolving end-use patterns, and shifting consumer demands. A primary driver is the exponential rise in chronic and genetic diseases, which has created an urgent need for precision therapeutics-an area where RNAi excels. Increased R&D investments from biopharma giants and startups alike are accelerating clinical pipelines, with several RNAi therapies already progressing through late-stage trials. Moreover, advances in high-throughput screening and bioinformatics tools are enabling rapid identification of novel RNAi targets, shortening development timelines. On the end-user front, the healthcare industry’s shift toward personalized medicine is boosting demand for customizable RNAi treatments. Additionally, the preference for minimally invasive administration routes-such as subcutaneous and intranasal-has intensified innovation in delivery systems. The commercial success of initial RNAi drugs has also increased investor confidence, triggering more funding toward RNAi-focused biotech firms. Regulatory agencies are becoming more accommodating as well, offering fast-track approvals and orphan designations for RNAi drugs targeting rare diseases. Furthermore, favorable reimbursement frameworks, especially in North America and Europe, are expanding patient access. The increasing adoption of RNAi in research and diagnostics further propels the market, making it one of the most dynamic segments in modern pharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the RNAi Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, Aptamer Drug Delivery); Application (Infectious Disease, Cardiology, Oncology, Neurology, Ophthalmology, Urology, Metabolic Disorders, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

• Alnylam Pharmaceuticals
• Aro Biotherapeutics
• Arrowhead Pharmaceuticals
• AstraZeneca
• BioNTech SE
• Dicerna Pharmaceuticals (acquired by Novo Nordisk)
• DTx Pharma (acquired by Novartis)
• GlaxoSmithKline (GSK)
• Ionis Pharmaceuticals
• Moderna, Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Roche Holding AG
• Sanofi
• Sarepta Therapeutics
• Silence Therapeutics
• Sirnaomics
• Switch Therapeutics

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • RNAi Drug Delivery - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Genetic Disorders Spurs Demand for RNAi-Based Therapeutics
  • Advances in Nanocarrier Technology Strengthen the Business Case for Targeted RNAi Delivery
  • Favorable Regulatory Support for Precision Medicine Drives Adoption of RNAi Platforms
  • Increased Investments in Rare Disease Research Expands Addressable Market Opportunity
  • Growing Pipeline of RNAi Candidates Accelerates Demand for Efficient Delivery Systems
  • Strategic Collaborations Between Biotech and Pharma Companies Propel Growth in RNAi Drug Delivery
  • Breakthroughs in Lipid Nanoparticle Formulations Drive Delivery Efficiency
  • Expanding Role of RNAi in Oncology Throws the Spotlight on Targeted Delivery Innovations
  • High Specificity and Gene Silencing Efficiency Sustain Growth Momentum
  • Government Funding and Public-Private Partnerships Boost RNAi Drug Development
  • Demand for Non-Viral Vectors in Gene Therapy Drives Innovation in Delivery Platforms
  • Development of Inhalable and Oral RNAi Delivery Systems Expands Patient Accessibility
  • Personalized Medicine Trends Reinforce Need for Scalable RNAi Delivery Technologies
  • Overcoming Immunogenicity Challenges Generates New Opportunities in RNAi Formulations
  • Mergers & Acquisitions Accelerate Access to Advanced RNAi Delivery Platforms
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World RNAi Drug Delivery Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for RNAi Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for RNAi Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for RNAi Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Nanoparticle Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Nanoparticle Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Nanoparticle Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Pulmonary Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Pulmonary Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Pulmonary Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Nucleic Acid Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Nucleic Acid Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Nucleic Acid Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Aptamer Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Aptamer Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Aptamer Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Urology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Urology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Urology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Metabolic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Infectious Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Ophthalmology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• JAPAN
  • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• CHINA
  • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• EUROPE
  • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for RNAi Drug Delivery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for RNAi Drug Delivery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for RNAi Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• FRANCE
  • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 74: France Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: France Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: France 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 77: France Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• GERMANY
  • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 80: Germany Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Germany Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Germany 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 83: Germany Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Germany Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Germany 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 86: Italy Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Italy Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Italy 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 89: Italy Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Italy Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Italy 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 92: UK Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: UK Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: UK 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 95: UK Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: UK Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: UK 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 98: Spain Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Spain Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Spain 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 101: Spain Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Spain Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Spain 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 104: Russia Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Russia Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Russia 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 107: Russia Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Russia Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Russia 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Rest of Europe Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Rest of Europe 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Rest of Europe Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Rest of Europe 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for RNAi Drug Delivery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 117: Asia-Pacific Historic Review for RNAi Drug Delivery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Asia-Pacific 15-Year Perspective for RNAi Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Asia-Pacific Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Asia-Pacific 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Asia-Pacific Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Asia-Pacific 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• AUSTRALIA
  • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 125: Australia Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Australia Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Australia 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 128: Australia Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Australia Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Australia 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• INDIA
  • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 131: India Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: India Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: India 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 134: India Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: India Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: India 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 137: South Korea Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: South Korea Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: South Korea 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 140: South Korea Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: South Korea Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: South Korea 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Asia-Pacific Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Asia-Pacific 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Asia-Pacific Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Asia-Pacific 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 149: Latin America Recent Past, Current & Future Analysis for RNAi Drug Delivery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 150: Latin America Historic Review for RNAi Drug Delivery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Latin America 15-Year Perspective for RNAi Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 152: Latin America Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Latin America Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Latin America 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 155: Latin America Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Latin America Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Latin America 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 158: Argentina Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Argentina Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Argentina 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 161: Argentina Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Argentina Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Argentina 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 164: Brazil Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Brazil Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Brazil 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 167: Brazil Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Brazil Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Brazil 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 170: Mexico Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Mexico Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Mexico 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 173: Mexico Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Mexico Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Mexico 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Latin America Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Latin America 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Latin America Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Latin America Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Latin America 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 182: Middle East Recent Past, Current & Future Analysis for RNAi Drug Delivery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 183: Middle East Historic Review for RNAi Drug Delivery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Middle East 15-Year Perspective for RNAi Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 185: Middle East Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Middle East Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Middle East 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 188: Middle East Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Middle East Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Middle East 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 191: Iran Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Iran Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Iran 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 194: Iran Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Iran Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Iran 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 197: Israel Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Israel Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Israel 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 200: Israel Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Israel Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Israel 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Saudi Arabia Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Saudi Arabia 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 206: Saudi Arabia Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Saudi Arabia Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Saudi Arabia 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 209: UAE Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: UAE Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: UAE 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 212: UAE Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: UAE Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: UAE 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Rest of Middle East Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Rest of Middle East 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 218: Rest of Middle East Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Rest of Middle East Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Rest of Middle East 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
• AFRICA
  • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 221: Africa Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Africa Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Africa 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
  • TABLE 224: Africa Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Africa Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Africa 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030

IV. COMPETITION